CVS Health Corporation (CVS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
$90.33 +0.42% NYSE • Public Delayed / 60s Snapshot
CVS Health Corporation (CVS) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
ROARABLE C • HOLD / WATCH
Cap $115.53B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERHOLD / WATCH • C
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D+ · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+2.2% Base Target
WHALE OPTIONS TUG-OF-WAR:53% Call Buyers ($11.1M)
47% PutsMax Pain: $89.00
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)
How CVS Turns Every Dollar of Sales Into Real Bottom-Line Profit
Free Cash Flow:$7.81B (1.9% FCF Margin)
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $357.78B
FY24
Rev $372.81B
FY25
Rev $402.07B
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $402.07B | 45% | 1.2% | $1.77B | $7.81B | 2.5% |
| FY 2024 | $372.81B | 44.7% | 2.3% | $4.61B | $6.33B | 4.6% |
| FY 2023 | $357.78B | 44% | 3.8% | $8.34B | -$2.67B | 4.2% |
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Forensic Quant Desk
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring CVS)
- ✓Live walkthrough of CVS's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
CVS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +8.36%▼ DESCENDING CHANNEL
2026-10-30O $91.95H $91.95L $89.90C $90.25VOL 8.19M
RES: $94.59SUP: $82.93SMA50: $91.23SMA200: $88.79
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CVS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
43.8%/yr Implied 5Y Growth
vs. +7.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CVS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
LLY → CVS Confirmed Filing
High-dollar GLP-1 prescriptions inflate CVS Pharmacy top-line revenue and Caremark PBM rebate administration volume, while depressing retail pharmacy gross margin % due to thin brand-drug dispensing spreads.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CVS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
CVS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is CVS Health Corporation (CVS)?
In FY 2025 (10-K), CVS converted $402.1B of revenue into a 45% gross margin, 1.2% operating margin, and $7.8B in free cash flow (1.9% FCF margin).